Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III biomarker-selected study of alectinib or entrectinib versus durvalumab in unresectable stage III NSCLC after chemoradiotherapy
CTR20221955Phase 3Active
- Sponsor
- Roche
- Start
- Feb 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of alectinib, entrectinib and durvalumab in non-small cell lung cancer (NSCLC) (4 cohorts), sponsored by Roche. Primary endpoint: Progression-free survival by blinded independent central review. Started Feb 2023; status: active.
02
Drugs
alectinibentrectinibdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20221955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221955.